The world’s first study which will deliberately expose volunteers to coronavirus to establish the smallest amount of virus needed to cause infection will take place in the UK.
hVIVO, a subsidiary of Dublin-based Open Orphan, is an industry-leading clinical company that will carry out the Covid-19 “human challenge” research backed by the UK government.
Starting in the next few weeks, the trial will involve up to 90 carefully selected, healthy adult volunteers being deliberately exposed to Covid-19 in a safe and controlled environment.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).